Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab for Untreated Brain Metastases in PD-L1+ NSCLC
NCT05840770Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Planned start Apr 2025; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05840770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840770.